OMass Therapeutics

Our Vice President of Pharmacology and incoming CSO Steven Charlton will be presenting at the GPCRs-Targeted Drug Discovery Summit taking place in London from 26-28 November.    Steven’s presentation, titled ‘Optimising Binding Kinetics Yields Insurmountable MC2 Receptor Antagonists for the Treatment of Diseases of ACTH Excess’ will take place at 4pm GMT on 27th November at 15Hatfields.   For more information, visit: https://lnkd.in/euGFheMq   #conference #drugdiscovery #masspec #biotech #LifeScience #innovation

Our CEO Ros Deegan was this year’s Women-Led Business Leader of the Year at the European Lifestars Awards - Celebrating Life Science Leaders!   The past year has been transformative for OMass with Ros showcasing exceptional leadership. Under her guidance, we’ve made significant advancements in our pipeline of small molecule therapeutics, targeting orphan diseases and immunological conditions. We have also nominated a clinical candidate for our lead programme, targeting the melanocortin-2 (#MC2) receptor for the treatment of congenital adrenal hyperplasia (#CAH).   Ros’ invitation to join the Prime Minister's Business Council and her role on the Board of the BioIndustry Association (BIA) reflects her outstanding reputation in the life sciences sector.   Under Ros’ leadership, we are excited to see what the next year holds!   #awards #drugdiscovery #masspec #biotech #lifescience #innovation #leadership

Our CEO Ros Deegan, CBO Melissa Faris and SVP of Finance and Operations Hsin Loke will be attending this year’s Jefferies London Healthcare Conference taking place from 19-21 November.   The conference will bring together leading executives to address near-and long-term investment opportunities as well as the current trends driving healthcare internationally.   If you’d like to connect to learn more about our pipeline of novel, differentiated small molecules against membrane proteins and intracellular complexes for rare diseases and immunological conditions, and lead programme targeting the melanocortin-2 (MC2) receptor for the treatment of congenital adrenal hyperplasia (CAH), please contact: info@omass.com    #Networking #Conference #DrugDiscovery

OMass Scientists Shahid Rehan, Ph.D. and Rei Matsuoka will be presenting at the Synchrotron SOLEIL - 32nd Protein Structure Determination in Industry (#PSDI) 2024 conference, taking place in Paris from 10-12 November.   Shahid will present on ‘Lipid Binding and Drug Discovery for the Lysosomal Solute Carrier SLC15A4’, while Rei’s presentation will focus on ‘Structural biology at OMass Therapeutics’.   For more information, visit: https://lnkd.in/erVS6DfM   #Innovation #DrugDiscovery #Structuralbiology #MassSpec #LifeScience #Biotech

Our new publication in Nature Portfolio - Communications explains why hydrogen deuterium exchange (#HDX) is a powerful technique for studying protein dynamics. The paper shows how we are able to utilise HDX-MS to understand the mechanism of action for drugs, and why we believe that early understanding of compound properties is essential for stratifying early hits and developing the structure-activity relationship (SAR) of a compound series.   Congratulations to our team: Jonathan Hopper, Ali Jazayeri, Maria Musgaard, Karolina Gherbi, Kathy Sengmany, Feng Qu, Mark Soave, Hsin-Yung (Jason) Yen.   To read the full paper in Nature Communications, visit: https://lnkd.in/d5H4_9Mu   #Innovation #DrugDiscovery #MassSpec #LifeScience #Biotech

We just grew by another great mind. We welcome Juliane Schwaderer PhD, who joins OMass Therapeutics as Director of R&D Project Management in Melissa Faris's team. Prior to joining #OMass, Juliane was a key contributor at MiroBio, an Oxford University spin-out, where she started as one of the first in vitro biologists. She later implemented a project management system that successfully advanced the pipeline to the clinic. Following MiroBio’s acquisition by Gilead Sciences, Juliane was responsible for the M&A integration process as part of the Oxford research leadership team. Juliane holds a PhD in Immunology from the University of Konstanz, Germany, and a Master’s in Nutritional Sciences. A huge welcome to Juliane, we are delighted to have you on board! #omass #Newjoiner #hiring #drugdiscovery #proteinbiochemisty #structuralbiology #immunology #orphandiseases #MassSpec #greatminds #opportunities #welcometotheteam #newstarter #onboarding

We are looking for a 2 year FTC Cell Biologist to join us at OMass Therapeutics in Winfried Barchet's team. This is a really exciting opportunity to be part of our growing team. For a detailed job description and to apply directly please visit our website https://lnkd.in/ddaju6xf #lifescience #immunology #pharmacology #cellbiology #science #massspec #drugdiscovery #scientist #development #hiring #jobs #team

Our Senior Director of Computational Chemistry Ben Tehan will be speaking at the Molecular Graphics and Modelling Society Computational Drug Design Symposium on 4 October at GSK's Medicines Research Centre in Stevenage. Ben’s presentation, titled ‘Molecular Dynamics in a Mass Spectrometry Company’ will take place at 2pm BST. The symposium is organised in honour of Frank Blaney, an early adopter of computational chemistry, known for his innovative work in molecular modelling and drug discovery.  #Symposium #MassSpec #LifeScience #OMass #Innovation 

Yesterday we announced the candidate nomination of our lead program targeting the melanocortin-2 (MC2) receptor, a GPCR for the adrenocorticotropic hormone (ACTH). The focus of our MC2 program has been to increase the receptor residency time to make OMass’ antagonists resistant to competition by the endogenous ligand. This can allow all patients suffering from conditions related to ACTH excess, including congenital adrenal hyperplasia and Cushing’s syndrome, to be treated. The nomination represents a key milestone for OMass as we progress our MC2 program towards the clinic. Read the full press release here: https://lnkd.in/e3_wSE8H Learn more about the potential of our MC2 program to treat Cushing’s disease and congenital adrenal hyperplasia in a blog by our CSO, Ali Jazayeri, here: https://lnkd.in/d79xqUxh #nomination #drugdiscovery #masspec #biotech #lifescience #innovation

OMass Senior Scientists Alex Wilkinson and Dillon Popat will be delivering poster presentations at the ELRIG UK – Drug Discovery 2024 taking place in ExCel, London from 2-3 October. Alex will present on how GSDMD nanobodies inhibit pore formation, but not GSDMD cleavage, and how this can be used in structural biology studies to determine the GSDMD-caspase-1 complex. Dillon will present on how native mass spectrometry identifies C-Terminal Palmitoylation of MC2R which facilitates interaction with effector proteins. To view the full programme visit: https://lnkd.in/e87sbXab #ELRIG #Conference #ELRIGDD24 #DrugDiscovery #NativeMasspec